Investor Presentation Q1-Q3 2020
88
Investor presentation First nine months of 2020
Region China at a glance.
Novo Nordisk®
Million
250
Diabetes trend
DKK
billion
25
8%
21%
Diabetes market by value and Novo
Nordisk market share
Novo Nordisk reported sales
First nine months
2020
Sales
(mDKK)
Growth²
100%
Long-acting insulin³
1,120
39%
Premix insulin4
200
20
I
20
3,662
13%
80%
GLP-1
Fast-acting insulin5
1,563
18%
150
15
42%1
60%
Human insulin
2,178
2%
Total insulin
8,523
14%
Insulin
100
212
197
10
10
9%1
40%
GLP-16
799
24%
163
Other Diabetes care?
1,204
(5%)
50
5
20%
10%¹
OAD
Diabetes care
10,526
12%
Obesity care
0
2019
0
0%
6
(17%)
(SaxendaⓇ)
Aug
2030
2045
2015
Population with diabetes
Diabetes growth rate
GLP-1 MS
-Insulin MS
Aug
2020
-OAD MS
Biopharm³
Total
304
19%
10,836
12%
Source: International Diabetes Federation: Diabetes Atlas 1th Edition 2000 and
Diabetes Atlas 9th Edition 2019
1 CAGR calculated for last 5-year period
Competitor insulin value market shares, as of Aug 2020: Novo Nordisk 47%, Sanofi
19%, Gan & Lee 13% and Eli Lilly 10%; Competitor GLP-1 value market shares, as of
Aug 2020: Novo Nordisk 92% and AstraZeneca 3%
OAD: Oral anti-diabetic; MS: Market share; Source: IQVIA MAT, Aug 2020 value figures
2 At constant exchange rates; 3 Comprises TresibaⓇ and LevemirⓇ: 4 Comprises
NovoMixⓇ:5 Comprises NovoRapidⓇ; 6 Comprises Victoza; 7 Comprises
Novo NormⓇ and needles; 8 Comprises primarily NovoSeven®, NovoEight® and
NorditropinⓇView entire presentation